Management of NSTEMI with Resolved Symptoms

Initial Management

The European Society of Cardiology recommends that all NSTEMI patients should be admitted to a monitored unit with continuous rhythm monitoring until diagnosis is confirmed, even if symptoms have resolved 1, 2
Rhythm monitoring for at least 24 hours (or until PCI, whichever comes first) is recommended for NSTEMI patients at low risk for cardiac arrhythmias 1, 2
Extended monitoring (>24 hours) is recommended for patients at increased risk for cardiac arrhythmias 1, 2

The European Society of Cardiology recommends that aspirin should be administered to all patients without contraindications at an initial oral loading dose of 150-300 mg (or 75-250 mg IV), followed by 75-100 mg daily for long-term treatment 1, 3
A P2Y12 receptor inhibitor should be added to aspirin and maintained for 12 months unless contraindicated or there is excessive bleeding risk 1, 3
Options for P2Y12 inhibitors include ticagrelor, prasugrel, and clopidogrel, with specific dosing recommendations for each 1, 3

The European Society of Cardiology recommends parenteral anticoagulation for all patients in addition to antiplatelet therapy 1, 3
For patients managed conservatively, unfractionated heparin (UFH) should be continued for at least 48 hours or until discharge, or alternatively, enoxaparin or fondaparinux can be administered for the duration of hospitalization (up to 8 days) 4, 5

The European Society of Cardiology recommends that risk stratification remains essential to guide management, even after symptom resolution 1, 2
High-sensitivity cardiac troponin (hs-cTn) should be measured serially for both diagnosis and prognostic assessment 1, 2
Echocardiography should be performed to evaluate regional and global left ventricular function 1, 2

The American Heart Association recommends that beta-blockers are indicated for all patients recovering from NSTEMI unless contraindicated, and should be continued indefinitely 6
ACE inhibitors should be given and continued indefinitely for patients with heart failure, LV dysfunction (LVEF <0.40), hypertension, or diabetes 6
Angiotensin receptor blockers (ARBs) are recommended for ACE inhibitor-intolerant patients with clinical or radiological signs of heart failure and LVEF <0.40 6

The European Society of Cardiology recommends that dual antiplatelet therapy should not be discontinued prematurely, even if symptoms have resolved, as this increases risk of recurrent events 1, 3
Patients should not be discharged too early based solely on symptom resolution; continuous monitoring is still required for at least 24 hours 1, 2
Risk stratification should not be overlooked in patients with resolved symptoms, as this guides optimal management strategy 1, 2